Evidence map›Paper›PMID 39000487›Full record

ArticleInternational journal of molecular sciences2024

Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers.

Islam M Miligy, Nahla Badr, Andrea Stevens, David Spooner, Rachna Awasthi, Yasmeen Mir, Anuj Khurana, Vijay Sharma, Usha Chandaran, Emad A Rakha and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Islam M MiligyCellular Pathology, Queen Elizabeth Hospital, Birmingham B15 2GW, UK.ORCID 0000-0001-5223-2426
Nahla BadrHistopathology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom 11352, Egypt.
Andrea StevensOncology Department, Queen Elizabeth Hospital, Birmingham B15 2GW, UK.
David SpoonerOncology Department, Queen Elizabeth Hospital, Birmingham B15 2GW, UK.
Rachna AwasthiCellular Pathology, Queen Elizabeth Hospital, Birmingham B15 2GW, UK.
Yasmeen MirPathology, Liverpool University Hospitals NHS Foundation Trust, Liverpool L7 8XP, UK.
Anuj KhuranaPathology, Liverpool University Hospitals NHS Foundation Trust, Liverpool L7 8XP, UK.
Vijay SharmaPathology, Liverpool University Hospitals NHS Foundation Trust, Liverpool L7 8XP, UK.
Usha ChandaranHistopathology Department, Salford Royal Hospital, Salford M6 8HD, UK.
Emad A RakhaHistopathology Department, Nottingham City Hospital, Nottingham NG5 1PB, UK.
Yasmine MauriceHistopathology Department, Heartlands General Hospital, Birmingham B9 5SS, UK.
Daniel KearnsCellular Pathology, Queen Elizabeth Hospital, Birmingham B15 2GW, UK.ORCID 0009-0005-3513-2112
Rami OweisHistopathology Department, Rotherham Foundation Trust, Rotherham S60 2UD, UK.
Amal AsarHistopathology Department, Rotherham Foundation Trust, Rotherham S60 2UD, UK.
Alastair IronsideDepartment of Pathology, NHS Lothian, Edinburgh EH41 3PF, UK.
Abeer M ShaabanCellular Pathology, Queen Elizabeth Hospital, Birmingham B15 2GW, UK.ORCID 0000-0001-5784-8705

Funding

Cancer Research UK C17422/A25154
6 · The paper itself

Abstract

Oestrogen receptor (ER)-positive breast cancer (BC) is generally well responsive to endocrine therapy. Neoadjuvant endocrine therapy (NAET) is increasingly being used for downstaging ER-positive tumours. This study aims to analyse the effect of NAET on a well-characterised cohort of ER-positive BC with particular emphasis on receptor expression. This is a retrospective United Kingdom (UK) multicentre study of 391 patients who received NAET between October 2012 and October 2020. Detailed analyses of the paired pre- and post-NAET morphological changes and hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression were performed. The median duration of NAET was 86 days, with median survival and overall survival rates of 380 days and 93.4%, respectively. A total of 90.3% of cases achieved a pathological partial response, with a significantly higher rate of response in the HER2-low cancers. Following NAET, BC displayed some pathological changes involving the tumour stroma including central scarring and an increase in tumour infiltrating lymphocytes (TILs) and tumour cell morphology. Significant changes associated with the duration of NAET were observed in tumour grade (30.6% of cases), with downgrading identified in 19.3% of tumours (

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyReceptors, EstrogenAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBiomarkers, TumorFemaleHumansMiddle AgedRetrospective StudiesAntineoplastic Agents, HormonalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Estrogenbreast cancerHER2neoadjuvant endocrine therapy (NAET)oestrogen receptorpathological responseprogesterone receptor

Identifiers

PMID39000487
PMCPMC11242101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.